Scientists develop Ozempic alternative

Scientists testing drug that may directly affect fat cells

Scientists are working on a new approach to treating excess weight. The experimental drug CBL-514 differs from popular agents such as Ozempic in its mechanism of action. While drugs in this group primarily affect appetite and satiety, CBL-514 targets adipose tissue directly.

The substance is intended to trigger the process of breaking down fat cells, allowing the body to gradually rid itself of some fat deposits. Researchers are studying the possibility of using the drug to reduce abdominal fat, specifically subcutaneous adipose tissue.

Scientists are particularly interested in visceral fat, which accumulates around internal organs. Its excess is linked to an increased risk of a number of metabolic disorders.

Preliminary clinical studies have shown that CBL-514 may contribute to a reduction in the volume of adipose tissue. However, there is no basis for claiming a complete absence of side effects. Among the reactions recorded during the trials were pain, redness, and swelling at the injection site.

CBL-514 is currently undergoing further clinical trials. The transition to the third phase is expected to provide more data on the efficacy and safety of the substance in a larger number of patients.

At the same time, it is too early to call CBL-514 a full replacement for Ozempic. The drug remains experimental, and its mechanism of action differs from that of drugs used for appetite control and obesity treatment. Final conclusions about the potential of the new approach can only be drawn after the completion of large-scale clinical trials.